Inclusion Criteria:

          -  Patients must provide informed written consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Clinical stage IV invasive mammary carcinoma that is ER, PR, HER2 negative (triple
             negative) previously documented by conventional methods (IHC, FISH). ER negative is
             defined as expression of ER in <1% cells, PR negative is defined as expression of PR
             in <1% cells, HER2 negative [acceptable methods of HER2 analysis include IHC (0, 1+),
             fluorescence in situ hybridization (FISH) with HER2/CEN-17 ratio <2, and/or
             chromogenic in situ hybridization (CISH) with HER2/CEN-17 ratio <2], as previously
             documented by histological analysis.

          -  Measurable disease, defined as at least one lesion that can be accurately measured in
             at least one dimension by Response Evaluation Criteria in Solid Tumors (RECIST)
             criteria 1.1

          -  Patients must have available tissue (archived formalin-fixed paraffin embedded blocks
             [FFPB] or fresh frozen tissue from original diagnosis or metastatic setting) for
             correlative studies; patients will not be able to start study drugs without tumor
             tissue availability; patients without available tumor tissue can still participate if
             willing to have a fresh biopsy of a metastatic lesion that is deemed to be medically
             safe (except for bone metastases)

          -  Any number of prior therapies as long as patients have adequate performance status and
             meet all other eligibility criteria.

          -  Patients must have adequate hematologic, hepatic, and renal function. All laboratory
             tests must be obtained less than 21 days from study entry. These include:

               -  Absolute neutrophil count (ANC) >= 1000/mm^3

               -  Platelet count >= 100,000/mm^3

               -  Hemoglobin >= 9 g/dL

               -  Creatinine =< 1.5 X upper limits of normal

               -  International normalized ratio (INR) =< 2

               -  Total serum bilirubin =< 1.5 x upper limit of normal (ULN) unless attributable to
                  Gilbert's syndrome

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
                  (or =< 4.0 x ULN if hepatic metastases are present)

          -  Patients must be able to swallow and retain oral medication

          -  Pre-menopausal patients must have a negative pregnancy test and agree to use birth
             control methods while participating in the study; women of childbearing age and their
             male counterparts should use a barrier method of contraception during and for 3 months
             following protocol therapy

          -  Patients must complete all screening assessments as outlined in the protocol

        Exclusion Criteria:

          -  Locally recurrent resectable breast cancer

          -  Known androgen receptor (AR) positive breast cancer (AR staining > 10% by
             immunohistochemistry is considered positive). If the AR status is unknown, the patient
             can go on study.

          -  Pregnant or lactating women

          -  Patients with untreated or symptomatic metastatic central nervous system (CNS)
             disease; however patients with CNS involvement may participate if:

               -  Clinically stable with respect to the CNS tumor at the time of screening and > 2
                  weeks from prior therapy completion (including radiation and/or surgery) to the
                  start of study treatment

               -  Not on steroid therapy

               -  Not receiving enzyme inducing anti-epileptic medications that were started for
                  brain metastases (these include carbamazepine, phenytoin, phenobarbital,
                  primidone, oxcarbazepine, topiramate, and vigabatrin)

          -  Patient has a history of another malignancy within 2 years prior to starting study
             treatment, except for cured basal cell carcinoma of the skin or excised carcinoma in
             situ of the cervix

          -  Patient who has had systemic therapy within 2 weeks (6 weeks for nitrosoureas or
             mitomycin C) prior to study entry

          -  Patient who has undergone major surgery =< 4 weeks prior to starting study treatment
             or who has not recovered from side effects of such procedure

          -  Patient has a clinically significant cardiac disease or impaired cardiac function,
             such as:

               -  The presence of cardiac disease, including a myocardial infarction within 6
                  months prior to study entry, unstable angina pectoris, New York Heart Association
                  class III/IV congestive heart failure, or uncontrolled hypertension

               -  Documented major electrocardiogram (ECG) abnormalities (not responding to medical
                  treatments)

               -  Major abnormalities documented by echocardiography (ECHO) with Doppler (for
                  example, moderate or severe heart valve function defect and/or left ventricular
                  [LV] ejection fraction < 50%, evaluation based on the institutional lower limit
                  of normal)

               -  Predisposing conditions that are consistent with development of aneurysms of the
                  ascending aorta or aortic stress (for example, family history of aneurysms,
                  Marfan-Syndrome, bicuspid aortic valve, evidence of damage to the large vessels
                  of the heart documented by computed tomography [CT] scan/magnetic resonance
                  imaging [MRI] with contrast)

          -  Patient who has any severe and/or uncontrolled medical conditions such as:

               -  Active or uncontrolled severe infection,

               -  Liver disease such as cirrhosis, decompensated liver disease, and chronic
                  hepatitis (i.e. quantifiable hepatitis B virus [HBV]-deoxyribonucleic acid [DNA])
                  and/or positive hepatitis B virus surface antigen [HbsAg], quantifiable hepatitis
                  C virus [HCV]-ribonucleic acid [RNA])

               -  Known severely impaired lung function (spirometry and diffusing capacity of the
                  lung for carbon monoxide [DLCO] 50% or less of normal and oxygen [O2] saturation
                  88% or less at rest on room air)

               -  Active bleeding diathesis

               -  Uncontrolled arterial hypertension defined by blood pressure > 170/100 mm Hg at
                  rest (average of 3 consecutive readings 5 min apart)

               -  Psychiatric illness/social situations that would compromise patient safety or
                  limit compliance with study requirements including maintenance of a
                  compliance/pill diary

          -  Prior treatment with paclitaxel in the metastatic setting is not allowed (patients who
             received neoadjuvant paclitaxel can be included).

          -  Chronic treatment with corticosteroids or other immunosuppressive agents

          -  Patient with impaired gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of oral drug (e.g. ulcerative disease, uncontrolled
             nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

          -  Patient with known positive serology for human immunodeficiency virus (HIV)

          -  Patient who does not apply highly effective contraception during the study and through
             the duration as defined below after the final dose of study treatment:

               -  Sexually active males should use a condom during intercourse while taking drug
                  and for 8 weeks after the final dose of study treatment and should not father a
                  child in this period; a condom is required to be used also by vasectomized men in
                  order to prevent delivery of the drug via seminal fluid

               -  Women of child-bearing potential, defined as all women physiologically capable of
                  becoming pregnant, unless they are using highly effective methods of
                  contraception during dosing and for 3 months following the discontinuation of
                  study treatment; highly effective contraception methods include:

                    -  Total abstinence (when this is in line with the preferred and usual
                       lifestyle of the subject; periodic abstinence [e.g., calendar, ovulation,
                       symptothermal, post-ovulation methods]) and withdrawal are not acceptable
                       methods of contraception

                    -  Female sterilization (have had surgical bilateral oophorectomy with or
                       without hysterectomy) or tubal ligation at least six weeks before taking
                       study treatment; in case of oophorectomy alone, only when the reproductive
                       status of the woman has been confirmed by follow up hormone level assessment

                    -  Male sterilization (at least 6 months prior to screening); for female
                       subjects on the study the vasectomized male partner should be the sole
                       partner for that subject

                    -  Combination of the following (a+b):

                         -  a. Placement of an intrauterine device (IUD) or intrauterine system
                            (IUS)

                         -  b. Barrier methods of contraception: condom or occlusive cap (diaphragm
                            or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal
                            suppository